Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jury Awards Nearly $334M To MGI Tech In Illumina Patent Suit

Executive Summary

The jury said the infringement, which involved patents on two-channel sequencing chemistry technology, had been “willful” and turned down Illumina’s counterclaims. 

You may also be interested in...



Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

Illumina Settles BGI Patent Battles For $325M

The settlement resolves a total of eight lawsuits between the companies on genetic sequencing technology and alleged antitrust violations.

Illumina Wins Injunction Keeping BGI Sequencers Off US Market

BGI, and its subsidiary MGI, can’t sell the infringing products in the US until after Illumina’s patents expire.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel